FLJ12716 Inhibitors
FLJ12716 inhibitors encompass a range of chemical compounds that act on various signaling pathways and cellular processes to achieve a decrease in the activity of the protein FLJ12716. Gefitinib, for example, targets the EGFR tyrosine kinase, which, when inhibited, would resultin a reduction of FLJ12716 activity if it functions as a downstream component in the EGFR pathway. Similarly, compounds such as Rapamycin and LY294002 disrupt mTOR and PI3K/AKT signaling respectively, pathways that may regulate FLJ12716, therefore leading to its decreased activity. The AKT pathway, a common route for many cellular processes, when inhibited by Triciribine, could also result in the downregulation of FLJ12716 if it is AKT-dependent. Cell cycle inhibitors like Palbociclib which target CDK4/6 could have an indirect effect on FLJ12716, assuming that it is regulated by the cell cycle. Additionally, kinase inhibitors such as U0126 and PD98059, which impede the MEK/ERK signaling cascade, along with SP600125, a JNK pathway inhibitor, and the ERK inhibitor SCH772984, would potentially attenuate the activity of FLJ12716 if it is a downstream target.
Inhibitors such as PP2 and ZM-447439 affect other crucial signaling mechanisms that could be connected to FLJ12716. PP2, which inhibits Src family tyrosine kinases, could lead to a reduction in FLJ12716 activity if it interacts within the Src kinase signaling network. On the other hand, ZM-447439 impedes Aurora kinases, essential for mitotic progression, which could result in the decreased function of FLJ12716 if it is associated with cell division or mitotic checkpoints. The specificity of these inhibitors to their targets ensures a targeted approach to decreasing FLJ12716 activity, each acting upon a unique aspect of cellular signaling or function that, while distinct, converges on the common outcome of inhibiting FLJ12716. This comprehensive approach to inhibition allows for a multifaceted understanding of the pathways FLJ12716 may be involved in, as well as the potential effects of its downregulation. Through the inhibition of upstream kinases, interference with signaling cascades, and disruption of cell cycle regulators, the activity of FLJ12716 can be effectively diminished, providing insight into the protein's role within the cellular context.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase, inhibiting its autophosphorylation and downstream signaling. Given that FLJ12716 is an assumed downstream effector in the EGFR pathway, the inhibition of EGFR would result in reduced activity of FLJ12716 by limiting upstream signaling events. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and together the complex inhibits mTOR, which is a key regulator of cell growth and proliferation. Since mTOR signaling can affect various downstream proteins, inhibition by Rapamycin could subsequently lead to a decrease in FLJ12716 activity if FLJ12716 is involved in mTOR related pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), blocking the PI3K/AKT signaling pathway. FLJ12716, if it is a downstream target of this pathway, would have decreased activity due to the inhibition of PI3K and reduced AKT activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another inhibitor of PI3K, irreversibly binding to and inhibiting the enzyme. This inhibition would decrease the activity of downstream proteins that rely on PI3K signaling, potentially including FLJ12716 if it is part of this signaling cascade. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the activation of AKT, a crucial kinase in many signaling pathways. Inhibition of AKT would mean reduced phosphorylation and activation of downstream proteins such as FLJ12716, assuming FLJ12716 is an AKT substrate. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. The cell cycle regulation by these kinases is critical, and their inhibition could lead to a downstream effect on proteins like FLJ12716 if they are regulated by the cell cycle. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $363.00 | 5 | |
This inhibitor targets ERK, a component of the MAPK/ERK pathway. By inhibiting ERK, this compound would prevent the phosphorylation and activation of proteins involved in this pathway, potentially affecting FLJ12716 activity if it is regulated by the MAPK/ERK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream activators of ERK in the MAPK/ERK pathway. The inhibition of MEK1/2 would lead to reduced ERK activity and could indirectly decrease the activity of FLJ12716 if it is part of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the stress-activated MAPK pathway. Inhibition of JNK could lead to decreased activity of its downstream targets, potentially including FLJ12716 if it is involved in this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK, which would reduce activation of the MAPK/ERK pathway. This could lead to a decrease in FLJ12716 activity if FLJ12716 functions downstream of this signaling route. | ||||||